Simultaneously blocking NRF2 signaling enhances oxidative damage caused by ROS and RNS, inducing ferroptosis and reshaping the immune microenvironment, effectively activating anti‐tumor immunity. The gene discussed is NFE2L2; the disease is neoplasm.